TARGET-AML
Nature Communications. Volume 13, Issue 1: p. 5487, 19 September 2022
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
Leukemia. Volume 33, Issue 8: p.1934-1943, 13 February 2019
10.1038/s41375-019-0402-3
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML
Blood. Volume 127, Issue 24 p.3094-3098, 3 May 2016 10.1182/blood-2016-04-709899
Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse
Cancer Res. Volume 76, Issue 8 p.2197-2205, 3 March 2016 10.1158/0008-5472.CAN-15-1015
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
J Clin Oncol. Volume 35, Issue 35 p.3964-3977, 25 October 2017 10.1200/JCO.2017.74.7451
Purpose
Children with acute myeloid leukemia (AML) whose disease is refractory to standard induction chemotherapy therapy or who experience relapse after initial response have dismal outcomes. We sought to comprehensively profile pediatric AML microRNA (miRNA) samples to identify dysregulated genes and assess the utility of miRNAs for improved outcome prediction.